Analysis of the Cochrane Review: Anti-vascular Endothelial Growth Factor for Prevention of Postoperative Vitreous Cavity Hemorrhage after Vitrectomy for Proliferative Diabetic Retinopathy. Cochrane Database Syst Rev. 2015;8:CD008214.

Authors

  • David Cordeiro Sousa Serviço de Oftalmologia. Hospital de Santa Maria. Centro Hospitalar Lisboa Norte. Lisboa. Portugal. Centro de Estudos das Ciências da Visão. Faculdade de Medicina. Universidade de Lisboa. Lisboa. Portugal.
  • Inês Leal Serviço de Oftalmologia. Hospital de Santa Maria. Centro Hospitalar Lisboa Norte. Lisboa. Portugal. Centro de Estudos das Ciências da Visão. Faculdade de Medicina. Universidade de Lisboa. Lisboa. Portugal.
  • João Costa Centro de Estudos de Medicina Baseada na Evidência. Faculdade de Medicina. Universidade de Lisboa. Lisboa. Portugal. Cochrane Portugal. Lisboa. Portugal.
  • António Vaz-Carneiro Centro de Estudos de Medicina Baseada na Evidência. Faculdade de Medicina. Universidade de Lisboa. Lisboa. Portugal. Cochrane Portugal. Lisboa. Portugal.

DOI:

https://doi.org/10.20344/amp.9437

Keywords:

Bevacizumab, Diabetic Retinopathy, Postoperative Hemorrhage/prevention & control, Randomized Controlled Trials as Topic, Vascular Endothelial Growth Factors/antagonists & inhibitors, Vitrectomy/adverse effects, Vitreous Hemorrhage/prevention & control

Abstract

Postoperative vitreous hemorrhage is a complication following vitrectomy for proliferative diabetic retinopathy, delaying visual recovery and making fundus examination and disease follow-up more difficult. Anti-vascular endothelial growth factor drugs such as bevacizumab, when injected in the vitreous cavity, reduce vascular proliferation and their use has been proposed to reduce the incidence of postoperative vitreous hemorrhage. The authors of this Cochrane systematic review evaluated all randomized controlled trials on the pre- or intraoperative use of anti-vascular endothelial growth factor to reduce postoperative vitreous hemorrhage occurrence after vitrectomy in patients with proliferative diabetic retinopathy. The results suggested that the use of intravitreal bevacizumab was effective in reducing early postoperative vitreous hemorrhage (i.e. at four weeks) occurrence, with a good safety profile. This work aims to summarize and discuss the findings and clinical implications of this Cochrane systematic review.

Downloads

Download data is not yet available.

Published

2017-08-31

How to Cite

1.
Sousa DC, Leal I, Costa J, Vaz-Carneiro A. Analysis of the Cochrane Review: Anti-vascular Endothelial Growth Factor for Prevention of Postoperative Vitreous Cavity Hemorrhage after Vitrectomy for Proliferative Diabetic Retinopathy. Cochrane Database Syst Rev. 2015;8:CD008214. Acta Med Port [Internet]. 2017 Aug. 31 [cited 2024 Nov. 13];30(7-8):513-6. Available from: https://actamedicaportuguesa.com/revista/index.php/amp/article/view/9437

Issue

Section

Cochrane Corner